Magne sanofi

Нами говоря, magne sanofi же, если рассматривать

Zithromax tablets contain azithromycin dihydrate equivalent to 250 mg, 500 mg or 600 mg of azithromycin. Zithromax powder for oral suspension (POS) contains zithromycin dihydrate equivalent to 200 mg magne sanofi azithromycin per 5 mL of suspension, magne sanofi reconstituted.

Excipient(s) with known effect. Excipient(s) with known effect in capsules: sugars as lactose. Excipient(s) remethan known effect in tablets: lactose. Excipient(s) with known effect in powder for oral suspension: sugars (each 5 mL of reconstituted product contains 3. Zithromax capsules are No. Zithroax 250 mg tablets are white to off magne sanofi, unscored, modified capsule shaped film coated tablets, engraved with with "Pfizer" on one side and "ZTM-250" on the other side.

Zithromax 500 mg tablets are white to off white, unscored, modified capsule shaped film coated tablets, engraved with "Pfizer" on one side and "ZTM-500" on the other side. Zithromax 600 mg tablets are magne sanofi to off white, scored, modified oval film coated tablets engraved with 'ZTM 600' on one side and 'PFIZER' on the other side.

Zithroax powder for oral suspension (POS) is a white to off-white powder. Azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity. Lower respiratory tract infections. Acute bacterial bronchitis due to Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis.

Community acquired pneumonia due to Streptococcus pneumoniae or Haemophilus influenzae in patients suitable for outpatient oral treatment. Magne sanofi acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy.

In clinical studies efficacy has been demonstrated against Chlamydia pneumoniae, Haemophilus influenzae, Magne sanofi pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus and Streptococcus magne sanofi. Upper respiratory tract infections.

Acute sinusitis due to Streptococcus pneumoniae or Haemophilus influenzae. Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes pharyngitis, including magne sanofi prophylaxis of rheumatic fever. Azithromycin appears to be magne sanofi as effective in the treatment of streptococcal pharyngitis.

However, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. Uncomplicated skin and skin structure infections. Uncomplicated infections due magne sanofi Staphylococcus aureus, Magne sanofi pyogenes or Streptococcus agalactiae. Abscesses usually require surgical drainage. Uncomplicated urethritis and cervicitis due to Chlamydia trachomatis.

At the recommended dose azithromycin cannot be magne sanofi upon to treat gonorrhoea or syphilis.

As with other drugs for the treatment of non-gonococcal infections, magne sanofi may mask or delay the symptoms of incubating gonorrhoea or syphilis. Appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required.

Azithromycin magne sanofi also indicated magne sanofi the treatment of Chlamydia trachomatis conjunctivitis and magne sanofi. Disseminated infection due to Mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy.

Azithromycin is indicated for use in children for the treatment of the following infections. Chlamydia trachomatis conjunctivitis and trachoma. Magne sanofi children 12 months or older. Azithromycin should be given as a single the lancet neurology dose. Tablets and POS may be taken with food. Administration of capsules with or following a meal significantly reduces the bioavailability.

Therefore, capsules must be taken at least 1 hour before or 2 hours after a meal. Sexually transmitted uncomplicated urethritis and cervicitis due to Chlamydia trachomatis. Conjunctivitis and trachoma due to Chlamydia trachomatis. Following IV therapy for the treatment of CAP. Prevention of disseminated MAC. All other indications (including outpatients initiated on oral treatment of CAP due to S.

Total dose of 1.

Further...

Comments:

There are no comments on this post...